Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Executive Vice President | June 01, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date June 01, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,433 |
Ending reported balance
After 2026-06-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-01 · Exercise / conversion · Acquired 639 · Balance 10,717 Row 2 · 2026-06-01 · Tax withholding · Disposed 284 · Balance 10,433 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-01 · Exercise / conversion · Disposed 639 · Balance 0 F1: Each Restricted Stock Unit represents a contingent right to receive one share of Issuer common stock and vested in one installment on June 1, 2026. F2: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of Issuer common stock and vested in one installment on June 1, 2026.
F2: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2024 Filed Feb 16, 2024 22:55 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 178 | $0.00 Strike: $560.56 | $0.00 |
DisclosureSEC source: 0000874716-24-000035 · wk-form4_1708124098.xml · derivative · entry 8 FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178 Underlying: Common Stock · 178 shares Expires 2034-02-13 F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2028. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:55 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 2,408 | $0.00 Strike: $560.56 | $0.00 |
DisclosureSEC source: 0000874716-24-000035 · wk-form4_1708124098.xml · derivative · entry 7 FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,408 Underlying: Common Stock · 2,408 shares Expires 2034-02-13 F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2025. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:55 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 162 | $560.56 | $90,810.72 |
DisclosureSEC source: 0000874716-24-000035 · wk-form4_1708124098.xml · nonDerivative · entry 6 FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,920 Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:55 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 57 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000035 · wk-form4_1708124098.xml · nonDerivative · entry 5 FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:55 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 56 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000035 · wk-form4_1708124098.xml · nonDerivative · entry 4 FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:55 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 52 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000035 · wk-form4_1708124098.xml · nonDerivative · entry 3 FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:55 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 97 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000035 · wk-form4_1708124098.xml · nonDerivative · entry 2 FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:55 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 108 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000035 · wk-form4_1708124098.xml · nonDerivative · entry 1 FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 8,198 | $0.00 Strike: $62.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000017 · wk-form4_1707516212.xml · derivative · entry 9 FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,198 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Grant of option to buy 4,099 shares of Issuer common stock that vested in five annual installments beginning on February 14, 2015, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,612 | $0.00 Strike: $62.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000017 · wk-form4_1707516212.xml · derivative · entry 8 FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,612 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Grant of option to buy 806 shares of Issuer common stock that vested in one installment on February 14, 2019, without giving effect to a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the 'Stock Split'). The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 412 | $575.80 | $237,230.71 |
DisclosureSEC source: 0000874716-24-000017 · wk-form4_1707516212.xml · nonDerivative · entry 7 FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,712 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $575.78 to a high of $575.845 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,173 | $575.02 | $1,824,527.99 |
DisclosureSEC source: 0000874716-24-000017 · wk-form4_1707516212.xml · nonDerivative · entry 6 FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,124 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $574.625 to a high of $575.39 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,125 | $573.98 | $645,723.11 |
DisclosureSEC source: 0000874716-24-000017 · wk-form4_1707516212.xml · nonDerivative · entry 5 FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,297 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $573.58 to a high of $574.56 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,279 | $572.78 | $1,305,364.94 |
DisclosureSEC source: 0000874716-24-000017 · wk-form4_1707516212.xml · nonDerivative · entry 4 FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,422 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $572.525 to a high of $573.47 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,209 | $572.14 | $691,711.94 |
DisclosureSEC source: 0000874716-24-000017 · wk-form4_1707516212.xml · nonDerivative · entry 3 FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,701 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $571.50 to a high of $572.45 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 8,198 | $62.00 | $508,276.00 |
DisclosureSEC source: 0000874716-24-000017 · wk-form4_1707516212.xml · nonDerivative · entry 2 FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,612 | $62.00 | $99,944.00 |
DisclosureSEC source: 0000874716-24-000017 · wk-form4_1707516212.xml · nonDerivative · entry 1 FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.